Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced ...

Pfizer recently reported positive Phase 2b results for its monthly injectable obesity drug PF-3944, showing up to 12.3% ...

In 2025, Pfizer PFE upped its efforts to rebuild its pipeline through acquisitions. Pfizer invested around $9 billion in M&A ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Pfizer forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit drugs with a series of pricey acquisitions. Revenue in 2026 will be $59.5 ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

Sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak with the end of the pandemic. Their ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...

Pfizer Balances COVID Drag With Pipeline Momentum in Latest Earnings Call The overall tone of Pfizer Inc.’s latest earnings call was cautiously optimistic, with management emphasizing underlying ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read the full analysis before buying.

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...